[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE60144123D1 - Verfahren zur Behandlung von Arzneimittelinduzierter peripherer Neuropathie und verwandten Krankheitsformen - Google Patents

Verfahren zur Behandlung von Arzneimittelinduzierter peripherer Neuropathie und verwandten Krankheitsformen

Info

Publication number
DE60144123D1
DE60144123D1 DE60144123T DE60144123T DE60144123D1 DE 60144123 D1 DE60144123 D1 DE 60144123D1 DE 60144123 T DE60144123 T DE 60144123T DE 60144123 T DE60144123 T DE 60144123T DE 60144123 D1 DE60144123 D1 DE 60144123D1
Authority
DE
Germany
Prior art keywords
peripheral neuropathy
related disorders
treating drug
induced peripheral
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60144123T
Other languages
English (en)
Inventor
Jack Diamond
Alvin J Glasky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spectrum Pharmaceuticals Inc
Original Assignee
Spectrum Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spectrum Pharmaceuticals Inc filed Critical Spectrum Pharmaceuticals Inc
Application granted granted Critical
Publication of DE60144123D1 publication Critical patent/DE60144123D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Magnetic Treatment Devices (AREA)
DE60144123T 2000-07-07 2001-07-06 Verfahren zur Behandlung von Arzneimittelinduzierter peripherer Neuropathie und verwandten Krankheitsformen Expired - Lifetime DE60144123D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21684400P 2000-07-07 2000-07-07

Publications (1)

Publication Number Publication Date
DE60144123D1 true DE60144123D1 (de) 2011-04-07

Family

ID=22808722

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60143850T Expired - Lifetime DE60143850D1 (de) 2000-07-07 2001-07-06 Verfahren zur behandlung von arzneimittelinduzierter peripherer neuropathie und verwandten krankheitsformen
DE60144123T Expired - Lifetime DE60144123D1 (de) 2000-07-07 2001-07-06 Verfahren zur Behandlung von Arzneimittelinduzierter peripherer Neuropathie und verwandten Krankheitsformen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60143850T Expired - Lifetime DE60143850D1 (de) 2000-07-07 2001-07-06 Verfahren zur behandlung von arzneimittelinduzierter peripherer neuropathie und verwandten krankheitsformen

Country Status (9)

Country Link
US (2) US6630490B2 (de)
EP (3) EP1334103B1 (de)
AT (2) ATE499103T1 (de)
AU (2) AU2001271908A1 (de)
DE (2) DE60143850D1 (de)
DK (2) DK1790344T3 (de)
ES (2) ES2385931T3 (de)
HK (1) HK1102367A1 (de)
WO (2) WO2002004452A2 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10504814A (ja) * 1994-07-25 1998-05-12 ジェイ． グラスキー，アルヴィン 一酸化炭素依存性グアニリルシクラーゼ修飾因子
US6759427B2 (en) 2001-04-20 2004-07-06 Spectrum Pharmaceuticals, Inc. Synthesis and methods of use of tetrahydroindolone analogues and derivatives
US20020156277A1 (en) * 2001-04-20 2002-10-24 Fick David B. Synthesis and methods of use of purine analogues and derivatives
US20030055249A1 (en) * 2001-07-17 2003-03-20 Fick David B. Synthesis and methods of use of pyrimidine analogues and derivatives
US7410981B2 (en) * 2002-06-14 2008-08-12 Takeda Pharmaceutical Company Limited Prodrugs of imidazole derivatives, for use as proton pump inhibitors in the treatment of e.g. peptic ulcers
EP1715921B1 (de) * 2003-09-25 2013-04-24 Abraxis BioScience, Inc. Tetrahydroindolon-derivate zur Behandlung von neurologischen Erkrankungen
US7906520B2 (en) 2003-11-13 2011-03-15 The General Hospital Corporation Methods for treating pain
CN1938307B (zh) * 2004-03-26 2010-06-16 大日本住友制药株式会社 9-取代的8-氧代腺嘌呤
JP2008540549A (ja) * 2005-05-09 2008-11-20 ハイドラ バイオサイエンシズ インコーポレイテッド Ｔｒｐｖ３機能調節用化合物
US8916550B2 (en) 2005-05-09 2014-12-23 Hydra Biosciences, Inc. Compounds for modulating TRPV3 function
TW200801003A (en) * 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
WO2007076875A2 (en) * 2006-01-06 2007-07-12 Aarhus Universitet Compounds acting on the serotonin transporter
US8138172B2 (en) * 2006-07-05 2012-03-20 Astrazeneca Ab 8-oxoadenine derivatives acting as modulators of TLR7
BRPI0715504A2 (pt) * 2006-08-01 2014-05-06 Spectrum Pharmaceuticals Inc Métodos e preparações farmacêuticas a fim de contribuir para o tratamento de neuropatia induzida por quimioterapia.
TW200831105A (en) * 2006-12-14 2008-08-01 Astrazeneca Ab Novel compounds
EP2139894B1 (de) * 2007-03-19 2011-10-26 AstraZeneca AB 9-substituierte 8-oxoadeninverbindungen als modulatoren des toll-like-receptor (tlr7)
EP2132209B8 (de) * 2007-03-19 2014-04-16 AstraZeneca AB 9-substituierte 8-oxoadeninverbindungen als modulatoren des toll-like-rezeptors (tlr7)
TW200902018A (en) * 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co Novel adenine compound
US8044056B2 (en) * 2007-03-20 2011-10-25 Dainippon Sumitomo Pharma Co., Ltd. Adenine compound
CN101687867B (zh) * 2007-05-08 2013-10-02 阿斯利康(瑞典)有限公司 具有免疫调节性质的咪唑并喹啉
WO2009031154A2 (en) * 2007-09-07 2009-03-12 Beta O2 Technologies Ltd. Air gap for supporting cells
DK2214487T3 (da) * 2007-10-11 2014-02-10 Glaxosmithkline Llc Nye sEH-inhibitorer og deres anvendelse
WO2009062134A1 (en) * 2007-11-09 2009-05-14 Cenomed Biosciences, Llc Treatment of post-traumatic stress disorder with tetrahydroindolone arylpiperazine compounds
PE20091156A1 (es) 2007-12-17 2009-09-03 Astrazeneca Ab Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo
US20110054168A1 (en) * 2008-01-17 2011-03-03 Ayumu Kurimoto Method for preparing adenine compound
US8865896B2 (en) 2008-01-17 2014-10-21 Astrazeneca Aktiebolag Method for preparing adenine compound
US9483755B2 (en) 2008-03-04 2016-11-01 Apple Inc. Portable multifunction device, method, and graphical user interface for an email client
US20090264443A1 (en) * 2008-04-18 2009-10-22 David Helton Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
EP2116618A1 (de) 2008-05-09 2009-11-11 Agency for Science, Technology And Research Diagnose und Behandlung des Kawasaki-Syndroms
EP2331047A4 (de) 2008-08-29 2013-10-30 Schulman A Inc Optimierte aromatisierte polymerzusammensetzungen
WO2011068233A1 (en) * 2009-12-03 2011-06-09 Dainippon Sumitomo Pharma Co., Ltd. Imidazoquinolines which act via toll - like receptors (tlr)
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
WO2012075340A2 (en) 2010-12-01 2012-06-07 Alderbio Holdings Llc Anti-ngf compositions and use thereof
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
WO2012080728A1 (en) 2010-12-16 2012-06-21 Astrazeneca Ab Imidazo [4, 5 -c] quinolin- 1 -yl derivative useful in therapy
EP2651943B1 (de) 2010-12-17 2017-03-22 Sumitomo Dainippon Pharma Co., Ltd. Purinderivate
WO2014063035A2 (en) * 2012-10-19 2014-04-24 Anthrogenesis Corporation Treatment of pain using amnion derived adherent cells
WO2015058141A1 (en) * 2013-10-18 2015-04-23 Virginia Tech Intellectual Properties, Inc. Nucleobase-containing monomers and copolymers
US9898162B2 (en) 2014-05-30 2018-02-20 Apple Inc. Swiping functions for messaging applications
TWI676127B (zh) 2014-09-02 2019-11-01 美商蘋果公司 關於電子郵件使用者介面之方法、系統、電子器件及電腦可讀儲存媒體
AU2016356694B2 (en) 2015-11-20 2021-07-29 Forma Therapeutics, Inc. Purinones as ubiquitin-specific protease 1 inhibitors
EP4408531A1 (de) * 2021-09-28 2024-08-07 University of Pittsburgh - of the Commonwealth System of Higher Education Verfahren zur behandlung von peripherer neuropathie

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3300380A (en) 1963-12-26 1967-01-24 Upjohn Co Diminishing toxicity of antiviral nu6-(hydroxyalkyl) adenines with 4-hydroxypyrazolo(3, 4-d) pyrimidine
US3321369A (en) 1965-05-26 1967-05-23 Abbott Lab Method of enhancing learning rate and retention level in warm blooded animals
US3484521A (en) 1966-06-23 1969-12-16 Int Chem & Nuclear Corp Enhancement of memory processes in mammals with basic addition salts of ribonucleic acid
BE759011A (fr) 1969-11-17 1971-05-17 Wellcome Found Aminopurines
DE2554453A1 (de) 1974-12-18 1976-06-24 Experimentales Et Cliniques De Medikament zur glykaemieregulierung
GB1530912A (en) 1975-02-13 1978-11-01 Wellcome Found Compositions containing 9-(2-hydroxy-3-alkyl)-adenines
US4138562A (en) 1977-02-09 1979-02-06 The Regents Of The University Of Minnesota Adenosine deaminase resistant antiviral purine nucleosides and method of preparation
US4221910A (en) 1978-09-15 1980-09-09 Newport Pharmaceuticals International, Inc. 9-(Hydroxy alkyl)purines
US4221909A (en) 1978-09-15 1980-09-09 Sloan-Kettering Institute For Cancer Research P-Acetamidobenzoic acid salts of 9-(hydroxyalkyl) purines
US4221794A (en) 1979-06-21 1980-09-09 Newport Pharmaceuticals International, Inc. Method of imparting immunomodulating and antiviral activity
US4340726A (en) 1980-03-14 1982-07-20 Newport Pharmaceuticals International, Inc. Esters
US4347360A (en) 1980-09-16 1982-08-31 Ens Bio Logicals Inc. Ring open nucleoside analogues
US4451478A (en) 1982-03-12 1984-05-29 Newport Pharmaceuticals International, Inc. Imidazole compounds
US4643992A (en) 1982-11-09 1987-02-17 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives
US5093318A (en) 1983-11-01 1992-03-03 Scripps Clinic And Research Foundation Immunostimulating guanosine derivatives and their pharmaceutical compositions
US4952693A (en) 1984-10-12 1990-08-28 Warner-Lambert Company Oxazolo-pyrimidine derivatives
JPH0696534B2 (ja) 1986-04-25 1994-11-30 ヘキストジヤパン株式会社 抗痴呆剤
US5495010A (en) 1987-04-17 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services Acid stable purine dideoxynucleosides
EP0691348A1 (de) 1988-04-19 1996-01-10 Institut Pasteur Aus Adenylat-Cyclase von B. Parapertussis hergestellte immunogemische Zusammensetzungen
US5256677A (en) 1989-05-23 1993-10-26 Abbott Laboratories Retroviral protease inhibiting compounds
US5187162A (en) 1989-09-15 1993-02-16 Gensia Pharmaceuticals Methods of treating neurodegenerative conditions
US5026687A (en) 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
US5091432A (en) 1990-03-28 1992-02-25 Glasky Alvin J 9-substituted hypoxanthine bi-functional compounds and their neuroimmunological methods of use
US5237051A (en) 1990-12-06 1993-08-17 Vanderbilt University Purified enterotoxin receptor protein
US5646155A (en) * 1994-05-12 1997-07-08 University Of Massachusetts Medical Center Drugs to prevent recurrent herpes virus infections
US5447939A (en) * 1994-07-25 1995-09-05 Glasky; Alvin J. Carbon monoxide dependent guanylyl cyclase modifiers and methods of use
US5801184A (en) 1994-07-25 1998-09-01 Glasky; Alvin J. Carbon monoxide dependent guanylyl cyclase modifiers and methods of use
JPH10504814A (ja) * 1994-07-25 1998-05-12 ジェイ． グラスキー，アルヴィン 一酸化炭素依存性グアニリルシクラーゼ修飾因子
US5795756A (en) 1995-12-11 1998-08-18 Johnson; Roger A. Method and compounds for the inhibition of adenylyl cyclase
US5948771A (en) 1996-01-31 1999-09-07 The Trustees Of Columbia University In The City Of New York Method for treating heart failure using tetrapyrroles and metallotetrapyrroles
US5801159A (en) 1996-02-23 1998-09-01 Galileo Laboratories, Inc. Method and composition for inhibiting cellular irreversible changes due to stress
EP0906090A1 (de) * 1996-03-15 1999-04-07 Somerset Pharmaceuticals, Inc. Verfahren zur vorbeugung und behandlung von periphärer neuropathie
WO1999057119A1 (en) 1998-05-04 1999-11-11 Neotherapeutics, Inc. Novel dopamine-like 9-substituted hypoxanthine and methods of use
WO1999056550A1 (en) 1998-05-04 1999-11-11 Neotherapeutics, Inc. Method for treating migraine in mammals
WO1999057120A1 (en) 1998-05-04 1999-11-11 Neotherapeutics, Inc. Novel serotonin-like 9-substituted hypoxanthine and methods of use
TWI246421B (en) * 1998-12-03 2006-01-01 Alcon Mfg Ltd Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases
US6297226B1 (en) * 1999-10-15 2001-10-02 Neotherapeutics, Inc. Synthesis and methods of use of 9-substituted guanine derivatives

Also Published As

Publication number Publication date
ATE499103T1 (de) 2011-03-15
US6630478B2 (en) 2003-10-07
DK1334103T3 (da) 2011-04-04
AU2001273212A1 (en) 2002-01-21
DE60143850D1 (de) 2011-02-24
EP1790344A2 (de) 2007-05-30
ES2385931T3 (es) 2012-08-03
HK1102367A1 (en) 2007-11-16
ES2420354T3 (es) 2013-08-23
WO2002004448A2 (en) 2002-01-17
DK1790344T3 (da) 2011-05-02
WO2002004452A2 (en) 2002-01-17
EP1334103A2 (de) 2003-08-13
EP1334104A2 (de) 2003-08-13
WO2002004448A3 (en) 2003-01-23
ATE495177T1 (de) 2011-01-15
WO2002004452A3 (en) 2003-01-03
AU2001271908A1 (en) 2002-01-21
US6630490B2 (en) 2003-10-07
EP1790344B1 (de) 2011-02-23
EP1790344A3 (de) 2007-06-27
EP1334103B1 (de) 2011-01-12
US20020055506A1 (en) 2002-05-09
US20020061899A1 (en) 2002-05-23

Similar Documents

Publication Publication Date Title
DE60144123D1 (de) Verfahren zur Behandlung von Arzneimittelinduzierter peripherer Neuropathie und verwandten Krankheitsformen
DE602004020263D1 (de) Amino-substituierte diaryläa,dücyclohepten- analoga als muscarinische agonisten und verfahren zur behandlung von neuropsychiatrischen erkrankungen
ATE362363T1 (de) Verwendung von tnf-alpha inhibitoren zur behandlung von nervenwurzelschäden
EA200600294A1 (ru) [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении
DE60219793D1 (de) Methode zur behandlung von zytokinvermittelten erkrankungen
DE60220422D1 (de) Substituierte pyrazoloverbindungen zur behandlung von entzündungen
ATE497778T1 (de) Lactoferrin-zusammensetzungen und verfahren zur behandlung von diabetischen ulcus
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
ATE521353T1 (de) Neues trisubstitutiertes 8h-pyridoä2,3- düpyrimidin-7-onderivat zur behandlung von durch csbp/p38kinase vermittelten krankheiten
DE60227095D1 (de) Zusammensetzungen und verfahren zur behandlung von abgebundenem gips
DE602005020580D1 (de) Stereoisomere verbindungen und verfahren zur behandlung von erkrankungen des magen-darm-trakts und des zentralen nervensystems
DE60034871D1 (de) Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
DE60014136D1 (de) Sapogenin derivate zur behandlung von kognitiven störungen
DE602004021847D1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
ATE415163T1 (de) Verfahren und zusammensetzungen zur behandlung von augenerkrankungen
ATE432930T1 (de) Benzosulfonamide derivate, deren verfahren zum herstellung, und deren verwendung zur behandlung von schmerzen
DE69941966D1 (de) Mittel und Verfahren zum Schutz, zur Behandlung und Reparatur von Bindegewebe
DE60237521D1 (de) Verfahren zur hemmung der ethylenreaktionen von pflanzen
DE602004023100D1 (de) Verbindungen und verfahren zur behandlung von dyslipidemie
DE69431199D1 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Schlafstörungen
DE59109225D1 (de) Verwendung von pyridylmethylsulfinyl-1h-benzimidazol derivaten zur behandlung durch helicobacter verursachter erkrankungen
DE69432626D1 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Desynchronisierungs-Erkankungen
ATE294584T1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
ATE334124T1 (de) Chinolinderivate, herstellungsprozess und verwendung zur behandlung von krankheiten, bei den s-cd23 involviert ist
DE60124255D1 (de) Verwendung von exogenen milchsäurebakterien zur behandlung von durch actinomyces naeslundii hervorgerufenen krankheiten